During the docking analysis, it was noted that out of the 44 compounds, Ashwagandhanolide and Withanolide sulfoxide had the potentiality to inhibit the four different proteins (viz., ERα, 17β-HSD1, TOP2A and p73 tetramerization domain) responsible for breast cancer. Here, TOP2A is linked to breast carcinoma.